Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Debt
Debt-to-Equity Ratio0.48
Current Ratio2.36
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio14.69
Forward P/E Ratio12.66
P/E Growth1.28
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales5.26
Cash Flow$26.2847 per share
Price / Cash12.19
Book Value$59.56 per share
Price / Book5.38
Profitability
EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins23.06%
Return on Equity38.17%
Return on Assets20.41%
Miscellaneous
Employees7,300
Outstanding Shares201,440,000
Market Cap$66.51 billion
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) announced its earnings results on Tuesday, July, 24th. The biotechnology company reported $5.80 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $5.22 by $0.58. The biotechnology company had revenue of $3.36 billion for the quarter, compared to analysts' expectations of $3.25 billion. Biogen had a return on equity of 38.17% and a net margin of 23.06%. The firm's quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.04 earnings per share. View Biogen's Earnings History.
When is Biogen's next earnings date?
How can I listen to Biogen's earnings call?
Biogen will be holding an earnings conference call on Tuesday, October 23rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8776501145.
What guidance has Biogen issued on next quarter's earnings?
Biogen issued an update on its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share (EPS) guidance of $24.90-25.50 for the period, compared to the Thomson Reuters consensus estimate of $23.91. The company issued revenue guidance of $13.0-13.2 billion, compared to the consensus revenue estimate of $12.96 billion.
What price target have analysts set for BIIB?
28 analysts have issued 12-month price objectives for Biogen's stock. Their predictions range from $262.15 to $470.00. On average, they anticipate Biogen's stock price to reach $382.8860 in the next year. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Biogen.
What is the consensus analysts' recommendation for Biogen?
28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 8 hold ratings and 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks. Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2.5% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (7/9/2018)
- 3. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
- 4. Citigroup Inc analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Aerie Pharmaceuticals (AERI), Halozyme Therapeutics (HALO), Repligen (RGEN) and China Biologic Products (CBPO).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 56)
- Mr. Jeffrey D. Capello, Exec. VP, CFO & Chief Accounting Officer (Age 53)
- Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 61)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
- Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 52)
Who are Biogen's major shareholders?
Biogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.31%), Swedbank (0.20%), State of New Jersey Common Pension Fund D (0.15%), Waverton Investment Management Ltd (0.15%), Bank of Montreal Can (0.12%) and Factory Mutual Insurance Co. (0.10%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including Swedbank, Manning & Napier Group LLC, Factory Mutual Insurance Co., Waverton Investment Management Ltd, Strs Ohio, Gateway Investment Advisers LLC, Saratoga Research & Investment Management and Xact Kapitalforvaltning AB. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, State of New Jersey Common Pension Fund D, Essex Investment Management Co. LLC, Randolph Co Inc, Bank of Montreal Can, Rhenman & Partners Asset Management AB, Montrusco Bolton Investments Inc. and First Hawaiian Bank. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $320.41.
How big of a company is Biogen?
Biogen has a market capitalization of $66.51 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
What is Biogen's official website?
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (NASDAQ BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
